On CGEN's third-quarter 2024 earnings call, investors' focus is likely to be on updates on its pipeline candidates being studied for cancer immunotherapies.

Counsel from Pfizer, Gilead, and Bristol Myers Squibb spoke on AI’s transformative power and risks, reports Marisa Woutersen ...

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major ...

Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck (NYSE: ...

The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $87.23, denoting a -1.05% change from the preceding trading day.

Charting, Price Performance, News & Related Contracts.